Abstract

FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLETS OF RIZATRIPTAN BENZOATE

Aditi Anil Kushare*

Abstract

In the present investigate is an attempt towards developing a formulation of Anti-migraine drug. The patents for uses and dosage form of Rizatriptan Benzoate will expire in the future so our target was to develop a dosage form as that of innovator product to file an ANDA application . Innovations in the area of Oral Dispersible Tablets are aimed at both increasing the performance of the dosage form by decreasing the disintegration time and increasing the patient compliance by masking the objectionable taste of the ingredient by direct compression technique. It containing Rizatriptan Benzoate as model drug used for the treatment of migraine disease. Formulation were prepared by using different Super disintegrate and suggested nine formulation F01-F09 & prepared Oral Dispersible Tablets F01-F09 by direct compression techniques containing Croscarmellose sodium and Crospovidone as Super disintegrant in different concentration (10.5,13.0 and 15.5mg). Optimized F08 formulation containing concentration of Crospovidone 10.5mg, Pregelatinized Starch 20mg, Aspartame 5mg as sweetener and Peppermint 1mg as flavor, Mannitol 94.77mg, Microcrystalline cellulose Avicel pH 101 37.20mg &Avicel pH 102 5mg, and Mag Stearate 12mg were used and further evaluated. Which having shows good flow properties of powder and final blend, less weight variation, Thickness 2.70-3.20 mm, Hardness 2.7-3.0 N, less disintegration time 11-15 sec and maximum drug content 99.94%. From this study, it can be concluded that Direct Compression technique has low cost, more potential and applicability in future for formulation of Orodispersible Tablet of Rizatriptan benzoate than that of Lyophilization Technique.

Keywords: Oral Dispersible Tablet, Rizatriptan Benzoate, Direct Compression, Superdisintegrant, Crospovidone, Croscarmellose Sodium.